Kiniksa(US:KNSA)2025-06-06 09:25Financial Performance & Growth - Kiniksa expects ARCALYST net revenue for 2025 to be between $590 million and $605 million[7, 34] - The company's Q1 2025 net revenue grew by approximately 75% year-over-year[13] - Kiniksa's Q1 2025 cash reserves are approximately $268 million[8, 35] - ARCALYST has achieved only about 13% penetration into its target population as of the end of Q4 2024[7, 18] Clinical Development - Kiniksa is developing KPL-387 for recurrent pericarditis, with a Phase 2/3 trial expected to begin in mid-2025 and Phase 2 data expected in the second half of 2026[7, 34] - The company is conducting IND-enabling activities with KPL-1161[7, 34] - KPL-387 is a fully human IgG2 monoclonal antibody that binds to IL-1R1, inhibiting IL-1α & IL-1β cytokine-mediated signaling[22] Commercial Strategy - Kiniksa's strategy focuses on driving future growth through innovation and execution, maximizing the current commercial opportunity for ARCALYST, and advancing its clinical portfolio[34] - The company aims to support the creation of an efficient network of care with regional centers of excellence and educate on data related to duration of disease and treatment to support longer-term persistence on ARCALYST[18]